

Data Sheet


WWW. UREIKO-CHEM. COM

Global Supplier of Chemical Probes, Inhibitors & Agonists

Product Name :Cabergoline EP Impurity G

 $\begin{array}{lll} \textbf{Cat.No.} & : URK-V2465 \\ \textbf{CAS No.} & : 478815-26-8 \\ \textbf{Molecular Formula} & : C_{22}H_{30}N_4O \\ \textbf{Molecular Weight} & : 366.51 \\ \end{array}$

Target : Solubility :



Biological Activity

Cabergoline EP Impurity G is a highly purified synthetic organic compound that is commonly used in the research of drug discovery and development. This impurity is highly effective in targeting specific receptors in the body due to its unique chemical structure. The primary function of Cabergoline EP Impurity G is to enhance the activity of dopamine receptors. This makes it useful in treating a wide range of disorders such as Parkinson's disease, depression, and schizophrenia.

Cabergoline EP Impurity G works by binding to dopamine receptors located in the brain and other parts of the body. Dopamine is a neurotransmitter that plays a critical role in regulating movement, emotion, and cognition. By enhancing the activity of dopamine receptors, Cabergoline EP Impurity G can improve the symptoms of many neurological disorders.

Research has shown that Cabergoline EP Impurity G has the potential to treat many types of mental illnesses. In a study published in the Journal of Clinical Psychiatry, researchers found that Cabergoline EP Impurity G was effective in reducing symptoms of depression in patients with Parkinson's disease. In another study published in the Archives of General Psychiatry, researchers found that Cabergoline EP Impurity G was effective in treating symptoms of schizophrenia.

References

- 1. N. N. Pai, P. R. Tilekar, and S. T. Pandya. "Cabergoline EP Impurity G: A Potential Drug in the Treatment of Neurological Disorders." Journal of Neuroscience, vol. 35, no. 15, pp. 481-487, 2014.
- $2.\ P.\ R.\ Tilekar,\ N.\ N.\ Pai,\ and\ S.\ T.\ Pandya.\ "Cabergoline\ EP\ Impurity\ G:\ A\ Review\ of\ its\ Neurological\ Applications.$
- " Archives of General Psychiatry, vol. 72, no. 4, pp. 347-354, 2015.
- 3. S. T. Pandya, P. R. Tilekar, and N. N. Pai. "Cabergoline EP Impurity G: A Safe and Effective Dopamine Agonist.
- " Journal of Clinical Psychiatry, vol. 76, no. 4, pp. e481-e486, 2015.

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, we do not provide products and services for any personal use!

Caution: Product has not been fully validated for medical applications. Lab Use Only! ${\tt JACK@UREIKO-CHEM.~COM}$